MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company ROA Ratio 2011-2026 | BMY
Annual ROA Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.83 | -9.66 | 8.43 | 6.53 | 6.4 | -7.61 | 2.65 | 14.06 | 3.0 | 13.22 | 4.93 | 5.94 | 6.64 | 5.46 | 11.25 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.06 | -9.66 | 5.27 |
Quarterly ROA Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.11 | -6.3 | -6.85 | -5.92 | -5.3 | 8.36 | 7.89 | 6.91 | 4.12 | 5.51 | 4.03 | 4.98 | 4.14 | -4.32 | -4.13 | -5.16 | -7.61 | 0.04 | -0.5 | 0.68 | 2.65 | 6.77 | 11.17 | 11.13 | 14.06 | 3.81 | 0.89 | 2.56 | 3.0 | 12.59 | 13.64 | 14.37 | 13.22 | 9.95 | 8.61 | 4.74 | 4.93 | 5.59 | 5.5 | 6.9 | 5.94 | 7.78 | 7.44 | 7.84 | 6.64 | 7.34 | 3.56 | 3.97 | 5.46 | 5.47 | 10.39 | 11.33 | 11.25 | 2.94 | 2.74 | 2.99 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.37 | -7.61 | 4.76 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.99 | $ 32.59 | -6.89 % | $ 877 M | USA |
|
Forte Biosciences
FBRX
|
-83.81 | $ 21.59 | -1.86 % | $ 280 M | USA |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
-5.17 | $ 92.14 | 1.33 % | $ 22.3 B | Germany |
 |
Grifols, S.A.
GRFS
|
0.99 | $ 7.98 | -1.6 % | $ 5.42 B |  Spain |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.7 | 3.03 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
-7.82 | $ 0.86 | -1.42 % | $ 143 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Incyte Corporation
INCY
|
18.49 | $ 97.16 | -0.26 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-6.51 | $ 75.56 | -0.29 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |